# American Vanguard Corp: Form 10-Q for the period ended Mar 31, 2018

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2018-05-08
- Accepted by EDGAR: May 8, 2018, 16:02 ET
- Period: 2018-03-31
- Accession: 0001564590-18-011782
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000156459018011782/avd-10q_20180331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000156459018011782/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2018-01-01 to 2018-03-31 | $63.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2018-01-01 to 2018-03-31 | $41.1m | us-gaap:GrossProfit |
| Operating income | 3 months, 2018-01-01 to 2018-03-31 | $7.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-01-01 to 2018-03-31 | $837.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-01-01 to 2018-03-31 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-01-01 to 2018-03-31 | $4.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-01-01 to 2018-03-31 | $0.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-01-01 to 2018-03-31 | $0.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-01-01 to 2018-03-31 | 29,972,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Dividends paid | 3 months, 2018-01-01 to 2018-03-31 | $438.0k | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2018-03-31 | $13.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-03-31 | $290.0m | us-gaap:AssetsCurrent |
| Total assets | at 2018-03-31 | $566.8m | us-gaap:Assets |
| Current liabilities | at 2018-03-31 | $134.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-03-31 | $252.6m | us-gaap:Liabilities |
| Long-term debt | at 2018-03-31 | $90.3m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2018-03-31 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2018-03-31 | $314.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 25,327 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

### MANAGEMENT OVERVIEW

The Company’s operating results the first three months of 2018 were improved over those of the same period of 2017, with net sales up 47% ($104,108 compared to $70,673, year over year), net income attributable to American Vanguard up 35% ($4,655 v. $3,452), gross profit up approximately 36% ($41,051 v. $30,084), gross margin down to 39% from 43% of net sales and operating expenses up about 35% ($33,700 v. $24,951), but down as a percentage of sales to 32% in 2018 as compared to 35% in 2017.

Top line sales performance was driven by two factors. First, we enjoyed sales of products from acquisitions that we completed largely during the second half of 2017, namely, the paraquat, abamectin and chlorothalil products (from an FTC-ordered divestiture), horticultural products from OHP, Inc., and multiple products sold into Central American through AgriCenter. Second, sales of our existing product lines also grew, led by our vector control products (replenishment following the 2017 heightened hurricane activity), strong in-season sales of our granular insecticide products and much improved sales of our fumigant products (after better spring weather in the western United States, as compared to last year). Gross profit increased as a result of continued improvement in factory performance, organic growth in the Company’s sales and the addition of products and businesses acquired during 2017. The decrease in gross margin percentage was driven by a change in mix including the acquired distribution businesses which drove strong sales but at lower margins. Operating expenses rose on an absolute basis, as the Company absorbed acquired businesses, continued to invest in the maintenance of several important products and continued development of our SIMPAS precision application technology, but dropped as a percentage of sales. Due to our 2017 acquisition activities, our level of borrowings increased in first three months of 2018 as compared to the same period of 2017. As a result, net interest expense was $837 in 2018, as compared to $298 in 2017. Our effective tax rate decreased to 26.0% for the three months ended March 31, 2018, as compared to 28.5% in 2017. Net income increased by 35% to $0.16 per share (basic and diluted) in the first quarter of 2018, as compared to $0.12 per share (basic and diluted) in the same period of 2017.

Our condensed consolidated financial statements as of March 31, 2018 include one-time adjustments to retained earnings related to changes in revenue recognition rules and accounting for income taxes, pursuant to U.S. GAAP, in the amounts of $2,214 and ($180) respectively.

When considering the condensed consolidated balance sheet, long-term debt increased by $12,839 to $90,325 for the three months ended March 31, 2018, as compared to $29,993 for the three months ended March 31, 2017. The increased level of debt was driven by six business and product acquisitions completed during the 2017 financial year and particularly in the final quarter of that year. Notwithstanding the increase in long term debt, the Company’s borrowing capacity increased to $124,936 as of March 31, 2018, as compared to $119,994 as of March 31, 2017.

### RESULTS OF OPERATIONS

### Quarter Ended March 31:

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Insecticides | $41,293 | $37,942 | $3,351 | 9% |
| Herbicides/soil fumigants/fungicides | 32,185 | 20,021 | 12,164 | 61% |
| Other, including plant growth regulators and distribution | 17,840 | 3,392 | 14,448 | 426% |
| Total crop | 91,318 | 61,355 | 29,963 | 49% |
| Non-crop, including distribution | 12,790 | 9,318 | 3,472 | 37% |
|  | $104,108 | $70,673 | $33,435 | 47% |
| Cost of sales: |  |  |  |  |
| Insecticides | $25,222 | $23,545 | $1,677 | 7% |
| Herbicides/soil fumigants/fungicides | 18,902 | 10,324 | 8,578 | 83% |
| Other, including plant growth regulators and distribution | 12,223 | 1,850 | 10,373 | 561% |
| Total crop | 56,347 | 35,719 | 20,628 | 58% |
| Non-crop including distribution | 6,710 | 4,870 | 1,840 | 38% |
|  | $63,057 | $40,589 | $22,468 | 55% |
| Gross profit: |  |  |  |  |
| Insecticides | $16,071 | $14,397 | $1,674 | 12% |
| Herbicides/soil fumigants/fungicides | 13,283 | 9,697 | 3,586 | 37% |
| Other, including plant growth regulators and distribution | 5,617 | 1,542 | 4,075 | 264% |
| Gross profit crop | 34,971 | 25,636 | 9,335 | 36% |
| Gross profit non-crop including distribution | 6,080 | 4,448 | 1,632 | 37% |
|  | $41,051 | $30,084 | $10,967 | 36% |
| Gross margin crop | 38% | 42% |  |  |
| Gross margin non-crop | 48% | 48% |  |  |
| Total gross margin | 39% | 43% |  |  |

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US | $69,815 | $52,244 | $17,571 | 34% |
| International | 34,293 | 18,429 | 15,864 | 86% |
|  | $104,108 | $70,673 | $33,435 | 47% |

Overall financial performance, both in terms of net sales and net income, for the Company improved for the quarter ended March 31, 2018 as compared to the same period in 2017. Net sales for the three months ended March 31, 2018 increased by nearly 47% to $104,108, as compared to $70,673 for the first quarter of 2017. Net sales for our crop business were $91,318, while net sales for our non-crop products were $12,790. Our domestic sales were $69,815 and our international sales were $34,293. A more detailed discussion of general market conditions and sales performance by category of products appears below.

While our participation in diverse markets has enabled us to achieve improved sales of existing products globally, our 2017 acquisitions have significantly expanded our top line sales into new markets. In fact, about $29,000 of the $33,435 in increased net sales arose from newly-acquired products, including domestic turf and ornamental products from OHP, Inc., three domestic crop products acquired through an FTC-ordered divestiture (paraquat, chlorothalonil and abamectin) and the many international product lines sold into Central America through AgriCenter.

Within the crop segment, in spite of low corn commodity pricing, we saw a first quarter increase in demand for our granular soil insecticides and post-emergent herbicide Impact, as compared to the quarter ended March 31, 2017. Higher soil fumigant demand drove our potato business, while challenging weather conditions in the Southeast US dampened early season sales of cotton products. The three products newly-acquired (paraquat, abamectin and chlorothalonil) and AgriCenter products bolstered the performance of our crop business. Our non-crop business also increased year-over-year; this was due primarily to both the incremental addition of the

OHP horticultural products and the replenishment of Gulf Coast channel inventories of our mosquito adulticide Dibrom that had been depleted by the heavy 2017 post-hurricane applications.

Across our crop business, net sales of our insecticides group were up approximately 9% to end at $41,293, as compared to $37,942 during the first quarter of 2017. Within this division, net sales of our granular soil insecticides were up approximately 13%. We saw a year-over-year increase in sales of our primary corn insecticide Aztec®, partially offset by a slight decrease in our SmartChoice® sales. Sales of Counter®, our nematode control product for corn and sugar beets, also increased in the quarter, as did Thimet® sales for use in peanuts and sugar cane. Sales of Mocap® and Nemacur® insecticides, which are used primarily outside the U.S. market, were both higher than the prior year. First quarter net sales of our non-granular insecticides used in crop applications such as our cotton insecticide Bidrin® decreased as compared to the same period of the prior year, primarily due to weather-related planting delays in the Southeast US region.

Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the first quarter of 2018 increased by approximately 61% to $32,185 from $20,021 in the comparable period of 2017. Net sales of our herbicide products increased by 74%, driven by steady performance from both our existing product portfolio and the incremental sales of our newly-acquired paraquat herbicide. Our soil fumigants business grew by approximately 16% from the prior year’s first quarter due to more favorable weather in the Western US region which facilitated the application of these liquid products. Year-over-year our fungicide sales rose on increased PCNB business and the addition of our newly acquired chlorothalonil product.

Within the group of other products (which includes AgriCenter products, plant growth regulators, molluscicides and tolling activity), net sales were about fivefold those of the first quarter of 2017. Most of this increase arose from AgriCenter sales into Costa Rica, Nicaragua, Honduras, and Panama. Higher quarterly sales of our growth regulator product NAA also contributed to the increase.

Our non-crop sales ended the first quarter of 2018 up 37% at $12,790 as compared to $9,318 for the same period of the prior year. Contributing factors were higher sales of our aerial-applied mosquito adulticide Dibrom driven by replenishment demand following the very strong fall season and the addition of our newly-acquired OHP horticultural products business. We posted relatively flat sales among our insecticide products for commercial pest control and slightly lower sales of our pharmaceutical products.

Our international sales increased 86% to $34,293, as compared to $18,429 for the first quarter of the prior year. This was mainly driven by the sales of our newly-acquired AgriCenter Central American business. Other positive factors were the sales of the three product lines, which were acquired from Syngenta in Mexico last year, stronger sales of Mocap in Northern Europe, increased demand for Vapam in Australia and Mexico and Dacthal sales in several countries such as Mexico and Canada.

Our cost of sales for the first quarter of 2018 ended at $63,057 or 61% of net sales. This compares to $40,589 or 57% of net sales in the same period of 2017. The increase in cost of sales as a percentage of net sales in 2018 was primarily driven by the impact of the mix change including the effect of acquired distribution businesses which drive high sales but at comparatively lower margins than our previously existing business.

Gross profit for the first quarter of 2018 improved by $10,967, or 36%, to end at $41,051, as compared to $30,084 for the first quarter of 2017. The change in mix described above had the impact of reducing gross margin percentage by approximately 5%. Offsetting this reduction, our factories continue to improve and overall under absorbed factory costs decreased by approximately $1,100, which improved gross margin by 1%. Gross margin percentage ended at 39% in the first quarter of 2018, as compared to 43% in the first quarter of the prior year. This performance was primarily driven by solid growth of our existing products, a continued strong manufacturing performance and the benefit gained from the product lines and businesses acquired in the second half of 2017.

Operating expenses increased by $8,749 or 35% to $33,700 for the three months ended March 31, 2018, as compared to the same period in 2017. The differences in operating expenses by department are as follows:

|  | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $9,481 | $6,706 | $2,775 | 41% |
| General and administrative | 11,164 | 7,704 | 3,460 | 45% |
| Research, product development and regulatory | 6,277 | 5,697 | 580 | 10% |
| Freight, delivery and warehousing | 6,778 | 4,844 | 1,934 | 40% |
|  | $33,700 | $24,951 | $8,749 | 35% |

22

- Selling expenses increased by $2,775 to end at $9,481 for the three months ended March 31, 2018, as compared to the same period of 2017. The main driver was an increase in activities from the newly acquired businesses.
- General and administrative expenses increased by $3,460 to end at $11,164 for the three months ended March 31, 2018, as compared to the same period of 2017. The main drivers were increases in amortization related to acquired product lines and businesses in 2017, and administrative activities from those newly acquired businesses.
- Research, product development costs and regulatory expenses increased by $580 to end at $6,277 for the three months ended March 31, 2018, as compared to the same period of 2017. The main drivers were increased product defense costs and regulatory expenses relating to the newly acquired businesses.
- Freight, delivery and warehousing costs for the three months ended March 31, 2018 were $6,778 or 6.5% of sales as compared to $4,844 or 6.8% of sales for the same period in 2017. This change is primarily driven by mix of product shipped during the period.

Interest costs net of capitalized interest were $837 in the first three months of 2018, as compared to $298 in the same period of 2017. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Q1 2018 Average Debt | Interest Expense | Interest Rate | Q1 2017 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $88,898 | $699 | 3.1% | $44,217 | $258 | 2.3% |
| Amortization of deferred loan fees | — | 59 | — | — | 62 | — |
| Amortization of other deferred liabilities | — | 102 | — | — | 9 | — |
| Other interest (income) expense | — | (6) | — | — | 7 | — |
| Subtotal | $88,898 | $854 | 3.8% | $44,217 | $336 | 3.0% |
| Capitalized interest | — | (17) | — | — | (38) | — |
| Total | $88,898 | $837 | 3.8% | $44,217 | $298 | 2.7% |

The Company’s average overall debt for the three months ended March 31, 2018 was $88,898, as compared to $44,217 for the three months ended March 31, 2017. Our borrowings in the three months ended March 31, 2018 are higher than the same period of the prior year primarily driven by the acquisitions completed in the second half of 2017 and the associated investment in expanded working capital. In addition to bank interest we incurred charges in 2018 related to discounted deferred compensation related to acquired businesses. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 3.1% for the three months ended March 31, 2018, as compared to 2.3% in 2017.

Income tax expense increased by $312 to end at an expense of $1,692 for the three months ended March 31, 2018, as compared to $1,380 for the comparable period in 2017. The effective tax rate for the quarter was 26.0%, as compared to 28.5% in the same period of the prior year. The change in effective tax rate is primarily driven by the implementation of the Tax Cuts and Jobs Act. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the three months ended March 31, 2018 we recognized a loss of $96 on our investment in TyraTech. This compared to a loss of $42 recognized in the comparable period of 2017. This reflected the latest information regarding the forecast for their financial performance for 2018. Furthermore, we recognized a loss in the amount of $121 on our investment in the Hong Kong joint venture which is a 50% owned equity investment.

Non-controlling interest represents the share of net income or loss that is attributable to the minority stockholder of our majority owned subsidiary, Envance. During the three months ended March 31, 2018 non-controlling interest amounted to a gain of $50, as compared to $39 in the same period of the prior year.

Our overall net income for the first three months of 2018 was $4,655 or $0.16 per basic and diluted share, as compared to $3,452 or $0.12 per basic and diluted share in the same quarter of 2017.

### LIQUIDITY AND CAPITAL RESOURCES

The Company used cash of $9,235 in operating activities during the three months ended March 31, 2018, as compared to generating $17,170 during the three months ended March 31, 2017. Included in the $9,235 are net income of $4,605, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $6,248. Stock based compensation of $1,309 and losses from equity method investments of $217 provided net cash inflows of $12,379, as compared to $9,911 for the same period of 2017.

During the first three months of 2018 the Company increased working capital by $26,629, as compared to a reduction of $3,978 during the same period of the prior year. Included in this change: inventories increased by $19,558 as part of our manufacturing plan for 2018 where we balance manufacturing cost recovery, plant capacity and customer needs. During the first quarter of 2017, our inventory increased by $1,366. Deferred revenue decreased by $2,740, as compared to $394 in the same period of 2017, driven by customer decision regarding demand, payment timing and our cash incentive programs. Our accounts payable balances increased by $9,613 driven by increased manufacturing activity (already noted) and compared with a reduction of $3,025 in the same period of 2017, reflecting a faster start up to production activity this year and the impact of the newly acquired businesses. Accounts receivables increased by $9,303 driven by a full quarter of AgriCenter sales and strong existing products sales growth. In the same period of 2017, accounts receivable decreased by $11,422. Prepaid expenses increased by $562 and income tax receivable decreased by $497. Accrued programs increased by $4,634, as compared to $6,612 in the prior year. The change reflected changed competitive pricing primarily related to certain products. Finally, other payables and accrued expenses decreased by $3,201, as compared to $5,657 in the prior year as a result of the incentive compensation accrual.

With regard to our program accrual, the reduction (as noted above), primarily reflects our mix of sales and customers in Q1 of 2018, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first quarter of 2018, the Company made accruals for programs in the amount of $13,542 and made payments in the amount of $8,908. During the first quarter of prior year, the Company made accruals in the amount of $13,543 and made payments in the amount of $6,931.

Cash used for investing activities was $2,368 for the three months ended March 31, 2018 as compared to $3,380 in March 31, 2017. The Company spent $1,553 on fixed assets acquisitions primarily focused on continuing to invest in manufacturing infrastructure and $815 related primarily to additional purchase accounting adjustments related to the AgriCenter business acquired in the fall of 2017.

During the three months ended March 31, 2018 financing activities provided $13,172, principally from the borrowings on the Company’s senior credit facility, as compared to utilizing $10,986 for the same period of the prior year. This included net borrowings of $12,800 from our credit facility in 2018, as compared to net repayments of $11,000 in 2017. In the first quarter of 2018, we paid dividends to stockholders amounting to $438, as compared to $289 in the same period of 2017.

The Company has various loans in place that together constitute the long-term loan balances shown in the condensed consolidated balance sheets as at March 31, 2018 and December 31, 2017. These are summarized in the following table:

| Long-term indebtedness ($000's) | March 31, 2018 | December 31, 2017 |
| --- | ---: | ---: |
| Revolving line of credit | $91,225 | $78,425 |
| Deferred loan fees | (900) | (939) |
| Total indebtedness | $90,325 | $77,486 |

As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West as agent, swing line lender and Letter of Credit issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA as defined in the Credit Agreement, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date.

At March 31, 2018, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $124,936, according to the terms of the Credit Agreement. This compares to an available borrowing capacity of $119,994 as of March 31, 2017. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for both the trailing twelve month period and proforma basis arising from acquisitions, which have improved, (2) net borrowings, which have increased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 14 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued and adopted accounting standards.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2017, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2017. However, as of January 1, 2018, we adopted the new revenue recognition standard.

## Market risk

As filed, 1,252 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2017.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

## Controls and procedures

As filed, 1,219 characters.

As of March 31, 2018, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of March 31, 2018, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. We implemented internal controls to ensure we adequately evaluated our contracts and properly assessed the impact of the new accounting standards under ASC 606.

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 407 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2017, filed on March 14, 2018. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.

Filed May 8, 2018.
Source: SEC EDGAR, the filing index for accession 0001564590-18-011782. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
